Min-Su Kim

Prof. Min-Su Kim

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2023 in Annals of Rehabilitation Medicine
Verified
Journal Article
Open access
PDF file
SYSeoyon Yang
Seoyon Yang
JPJin-Woo Park
Jin-Woo Park
KMKyunghoon Min
Kyunghoon Min
YLYoon Se Lee
Yoon Se Lee
YSYoung-Jin Song
Young-Jin Song
KCKyoung Hyo Choi
Kyoung Hyo Choi
Objective: Dysphagia is a common clinical condition characterized by difficulty in swallowing. It is sub-classified into oropharyngeal dysphagia, which refers to problems in the mouth and pharynx, and esophageal dysphagia, which refers to problems in the esophageal body and esophagogastric junction. Dysphagia can have a significant negative impact one’s physical health and quality of life as its severity increases. Therefore, proper assessment and management of dysphagia are critical for improving swallowing function and preventing complications. Thus a guideline was developed to provide evidence-based recommendations for assessment and management in patients with dysphagia. Methods: Nineteen key questions on dysphagia were developed. These questions dealt with various aspects of problems related to dysphagia, including assessment, management, and complications. A literature search for relevant articles was conducted using Pubmed, Embase, the Cochrane Library, and one domestic database of KoreaMed, until April 2021. The level of evidence and recommendation grade were established according to the Grading of Recommendation Assessment, Development and Evaluation methodology.Results: Early screening and assessment of videofluoroscopic swallowing were recommended for assessing the presence of dysphagia. Therapeutic methods, such as tongue and pharyngeal muscle strengthening exercises and neuromuscular electrical stimulation with swallowing therapy, were effective in improving swallowing function and quality of life in patients with dysphagia. Nutritional intervention and an oral care program were also recommended. Conclusion: This guideline presents recommendations for the assessment and management of patients with oropharyngeal dysphagia, including rehabilitative strategies.

23 September 2021 in Oncology Letters
Verified
Journal Article
Open access
PDF file
SKSoon Young Kwon
Soon Young Kwon
KCKyung Ju Chun
Kyung Ju Chun
HKHong Kwon Kil
Hong Kwon Kil
NJNarae Jung
Narae Jung
HSHyun-Ah Shin
Hyun-Ah Shin
MKMin-Su Kim
Min-Su Kim
The present study aimed to investigate expression of β2‑adrenergic receptor (AR), the effect of the stress‑related neurotransmitter norepinephrine (NE) on cell viability, proliferation and the therapeutic effect of propranolol, which is a typical β‑blocker in various type of head and neck cancers for the first time. The β2‑AR expression was investigated using immunohistochemistry and an immunoreactive scoring (IRS) system in 57 different head and neck cancer specimens, and reverse transcriptase‑polymerase chain reaction and western blotting in four head and neck cancer cell lines (HNCCLs). Cell viability and proliferation assays were performed using 0, 1, 5 and 10 µM of NE and 1 µM of propranolol in four HNCCLs. The expression of β2‑AR was positive in the majority of head and neck cancer tissues (55/57, 96.5%); however, it was significantly higher in oral cavity cancer than in pharyngeal cancer (median IRS: 9 vs. 3; P<0.001). All HNCCLs exhibited β2‑AR expression, with a higher expression level detected in the oral cavity cancer cell line than in the others. NE stimulated viability (oral cavity, 206%; larynx, 156%; pharynx, 130%; nasal cavity, 137%; 10 µM NE) and proliferation (124, 176, 131 and 127%, respectively) in a dose‑dependent manner in all HNCCLs. Conversely, propranolol attenuated such viability (55, 42, 18 and 22%, respectively) and proliferation (22, 40, 61 and 48%, respectively). In conclusion, the viability and proliferation of various head and neck cancers may be directly stimulated by stress and this may be attenuated by β‑blockers.

28 February 2023 in Clinical and Experimental Otorhinolaryngology
Verified
Journal Article
Open access
PDF file
JPJun-Ook Park
Jun-Ook Park
JKJOO HYUN KIM
JOO HYUN KIM
YJYoung Hoon Joo
Young Hoon Joo
SKSang-Yeon Kim
Sang-Yeon Kim
GKGeun-Jeon Kim
Geun-Jeon Kim
SKSoon-Young Kwon
Soon-Young Kwon
The aim of this study was to develop evidence-based recommendations for determining the surgical extent in patients with locally invasive differentiated thyroid cancer (DTC). Locally invasive DTC with gross extrathyroidal extension invading surrounding anatomical structures may lead to several functional deficits and poor oncological outcomes. At present, the optimal extent of surgery in locally invasive DTC remains a matter of debate, and there are no adequate guidelines. On October 8, 2021, four experts searched the PubMed, Embase, and Cochrane Library databases; the identified papers were reviewed by 39 experts in thyroid and head and neck surgery. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the quality of evidence, and to develop and report recommendations. The strength of a recommendation reflects the confidence of a guideline panel that the desirable effects of an intervention outweigh any undesirable effects, across all patients for whom the recommendation is applicable. After completing the draft guidelines, Delphi questionnaires were completed by members of the Korean Society of Head and Neck Surgery. Twenty-seven evidence-based recommendations were made for several factors, including the preoperative workup; surgical extent of thyroidectomy; surgery for cancer invading the strap muscles, recurrent laryngeal nerve, laryngeal framework, trachea, or esophagus; and surgery for patients with central and lateral cervical lymph node involvement. Evidence-based guidelines were devised to help clinicians make safer and more efficient clinical decisions for the optimal surgical treatment of patients with locally invasive DTC.

1 January 2018 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
MKMin-Su Kim
Min-Su Kim
SKSo Young Kim
So Young Kim
HCHyo Geun Choi
Hyo Geun Choi
Kim MS, et al. J Korean Med Sci. 2018 Jan;33(10):e78. https://doi.org/10.3346/jkms.2018.33.e78

30 April 2024 in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
MKMin-Su Kim
Min-Su Kim
JLJang Won Lee
Jang Won Lee
MHMin Kyung Hyun
Min Kyung Hyun
YSYOUNG SHIN SONG
YOUNG SHIN SONG
Background: Current research has not investigated the effect of thyroid-stimulating hormone suppression therapy with levothyroxine on the risk for developing subsequent primary cancers (SPCs). This study aimed to investigate the association between levothyroxine dosage and the risk for SPCs in thyroid cancer patients.Methods: We conducted a nationwide population-based retrospective cohort study form Korean National Health Insurance database. This cohort included 342,920 thyroid cancer patients between 2004 and 2018. Patients were divided into the non-levothyroxine and the levothyroxine groups, the latter consisting of four dosage subgroups according to quartiles. Cox proportional hazard models were performed to evaluate the risk for SPCs by adjusting for variables including cumulative doses of radioactive iodine (RAI) therapy.Results: A total of 17,410 SPC cases were observed over a median 7.3 years of follow-up. The high-dose levothyroxine subgroups (Q3 and Q4) had a higher risk for SPC (adjusted hazard ratio [HR], 1.14 and 1.27; 95% confidence interval [CI], 1.05–1.24 and 1.17– 1.37; respectively) compared to the non-levothyroxine group. In particular, the adjusted HR of stomach (1.31), colorectal (1.60), liver and biliary tract (1.95), and pancreatic (2.48) cancers were increased in the Q4 subgroup. We consistently observed a positive association between high levothyroxine dosage per body weight and risk of SPCs, even after adjusting for various confounding variables. Moreover, similar results were identified in the stratified analyses according to thyroidectomy type and RAI therapy, as well as in a subgroup analysis of patients with good adherence.Conclusion: High-dose levothyroxine use was associated with increased risk of SPCs among thyroid cancer patients regardless of RAI therapy.

28 October 2020 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
SKSoon-Young Kwon
Soon-Young Kwon
KCKyung Ju Chun
Kyung Ju Chun
HKHong Kwon Kil
Hong Kwon Kil
KOKyoung Ho Oh
Kyoung Ho Oh
CKChulhan Kim
Chulhan Kim
MKMin-Su Kim
Min-Su Kim